journal
Journals Current Pharmacogenomics and P...

Current Pharmacogenomics and Personalized Medicine

https://read.qxmd.com/read/29657584/dynamic-biomarkers-of-response-to-antiangiogenic-therapies-in-colorectal-cancer-a-review
#1
REVIEW
Jesus Rodriguez-Pascual, Antonio Cubillo
Background: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several stu-dies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal anti-body. Conclusion: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice...
December 2017: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/25045411/ethical-political-and-societal-implications-of-the-open-access-journal-movement-in-the-era-of-economic-crisis-with-emphasis-on-public-health-pharmacogenomics
#2
JOURNAL ARTICLE
Nicola Luigi Bragazzi
Publication of the research outputs is a vital step of the research processes and a gateway between the laboratory and the global society. Open Access is revolutionizing the dissemination of scientific ideas, particularly in the field of public health pharmacogenomics that examines the ways in which pharmacogenomics impacts health systems and services at a societal level, rather than a narrow bench to bedside model of translation science. This manuscript argues that despite some limitations and drawbacks, open access has profound ethical, political and societal implications especially on underdeveloped and developing countries, and that it provides opportunities for science to grow in these resource-limited countries, particularly in the era of a severe economic and financial crisis that is imposing cuts and restrictions to research...
December 2013: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/24497894/a-conceptual-model-of-psychoneurological-symptom-cluster-variation-in-women-with-breast-cancer-bringing-nursing-research-to-personalized-medicine
#3
Angela R Starkweather, Debra E Lyon, R K Elswick, Alison J Montpetit, Yvette Conley, Nancy L McCain
Personalized medicine applies knowledge about the patient's individual characteristics in relation to health and intervention outcomes, including treatment response and adverse side-effects, to develop a tailored treatment plan. For women with breast cancer, personalized medicine has substantially improved the rate of survival, however, a high proportion of these women report multiple, co-occurring psychoneurological symptoms over the treatment trajectory that adversely affect their quality of life. In a subset of these women, co-occurring symptoms referred to as symptoms clusters, can persist long after treatment has ended...
September 2013: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/23885285/situating-nutri-ethics-at-the-junction-of-nutrigenomics-and-nutriproteomics-in-postgenomics-medicine
#4
Nicola Luigi Bragazzi
Food has societal, economic, medical and ethical implications, being fundamental for life. It plays an important role also in sports medicine, since a healthy diet is an important part of an athlete's training. Nutrigenomics and nutriproteomics are emerging as a result of a convergence of nutritional, genomics and proteomics knowledge strands in the postgenomics era. These fields of inquiry present an opportunity for the design of customized diets potentially able to counterbalance the extant obesity epidemic and remedy metabolic diseases, among others...
June 2013: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/23885284/commercial-opportunities-and-ethical-pitfalls-in-personalized-medicine-a-myriad-of-reasons-to-revisit-the-myriad-genetics-saga
#5
Derek So, Yann Joly
In 1996, the US-based biotechnology company Myriad Genetics began offering genetic diagnostic tests for mutations in the genes BRCA1 and BRCA2, which are linked to hereditary breast and ovarian cancer. Since that time, Myriad has been a forerunner in the field of personalized medicine through the use of effective commercialization strategies which have been emulated by other commercial biotechnology companies. Myriad's strategies include patent acquisition and active enforcement, direct-to-consumer advertising, diversification, and trade secrets...
June 2013: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/23531886/public-health-pharmacogenomics-and-the-design-principles-for-global-public-goods-moving-genomics-to-responsible-innovation
#6
JOURNAL ARTICLE
Vural Ozdemir, Alexander Borda-Rodriguez, Edward S Dove, Lynnette R Ferguson, Farah Huzair, Vangelis G Manolopoulos, Mario Masellis, Djims Milius, Louise Warnich, Sanjeeva Srivastava
No abstract text is available yet for this article.
March 24, 2013: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/24795785/taking-the-kidney-personally-the-quest-for-novel-antigens-of-idiopathic-membranous-nephropathy-through-proteomic-approaches-per-ardua-ad-astra
#7
JOURNAL ARTICLE
Ana Konvalinka, Sanjeeva Srivastava, Mario Masellis
No abstract text is available yet for this article.
March 1, 2013: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/24179558/mechanisms-of-adipocytokine-mediated-trastuzumab-resistance-in-her2-positive-breast-cancer-cell-lines
#8
Samantha E Griner, Katherine J Wang, Jayashree P Joshi, Rita Nahta
Acquired resistance to trastuzumab is a clinical problem in the treatment of HER2-over-expressing metastatic breast cancer. Importantly, an earlier report suggested that high body mass index was associated with reduced overall survival and reduced time to progression in patients with early stage or metastatic HER2-positive breast cancer treated with trastuzumab. Adipocyte-secreted factors may stimulate growth of HER2-positive cancers, blocking the growth inhibitory action of trastuzumab. Leptin and growth differentiation factor 15 (GDF15) are two adipocytokines that have been reported to stimulate HER2-PI3K signaling...
March 1, 2013: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/23185213/epigenetic-regulation-in-particulate-matter-mediated-cardiopulmonary-toxicities-a-systems-biology-perspective
#9
Ting Wang, Joe Gn Garcia, Wei Zhang
Particulate matter (PM) air pollution exerts significant adverse health effects in global populations, particularly in developing countries with extensive air pollution. Understanding of the mechanisms of PM-induced health effects including the risk for cardiovascular diseases remains limited. In addition to the direct cellular physiological responses such as mitochondrial dysfunction and oxidative stress, PM mediates remarkable dysregulation of gene expression, especially in cardiovascular tissues. The PM-mediated gene dysregulation is likely to be a complex mechanism affected by various genetic and non-genetic factors...
December 2012: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/23467392/role-of-statistical-random-effects-linear-models-in-personalized-medicine
#10
Francisco J Diaz, Hung-Wen Yeh, Jose de Leon
Some empirical studies and recent developments in pharmacokinetic theory suggest that statistical random-effects linear models are valuable tools that allow describing simultaneously patient populations as a whole and patients as individuals. This remarkable characteristic indicates that these models may be useful in the development of personalized medicine, which aims at finding treatment regimes that are appropriate for particular patients, not just appropriate for the average patient. In fact, published developments show that random-effects linear models may provide a solid theoretical framework for drug dosage individualization in chronic diseases...
March 2012: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/22611463/pharmacogenomics-in-primary-care-a-crucial-entry-point-for-global-personalized-medicine
#11
Gillian Bartlett, Nathalie Zgheib, Aresha Manamperi, Wei Wang, Candan Hizel, Rabia Kahveci, Yasemin Yazan
No abstract text is available yet for this article.
2012: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/22545073/end-of-the-beginning-and-public-health-pharmacogenomics-knowledge-in-mode-2-and-p5-medicine
#12
Vural Ozdemir, Erik Fisher, Edward S Dove, Hilary Burton, Galen E B Wright, Mario Masellis, Louise Warnich
No abstract text is available yet for this article.
January 1, 2012: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/23049672/top-three-pharmacogenomics-and-personalized-medicine-applications-at-the-nexus-of-renal-pathophysiology-and-cardiovascular-medicine
#13
JOURNAL ARTICLE
Murielle Bochud, Michel Burnier, Idris Guessous
Pharmacogenomics is a field with origins in the study of monogenic variations in drug metabolism in the 1950s. Perhaps because of these historical underpinnings, there has been an intensive investigation of 'hepatic pharmacogenes' such as CYP450s and liver drug metabolism using pharmacogenomics approaches over the past five decades. Surprisingly, kidney pathophysiology, attendant diseases and treatment outcomes have been vastly under-studied and under-theorized despite their central importance in maintenance of health, susceptibility to disease and rational personalized therapeutics...
December 2011: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/22523528/towards-an-ecology-of-collective-innovation-human-variome-project-hvp-rare-disease-consortium-for-autosomal-loci-radical-and-data-enabled-life-sciences-alliance-delsa
#14
Vural Ozdemir, David S Rosenblatt, Louise Warnich, Sanjeeva Srivastava, Ghazi O Tadmouri, Ramy K Aziz, Panga Jaipal Reddy, Aresha Manamperi, Edward S Dove, Yann Joly, Ma'n H Zawati, Candan Hızel, Yasemin Yazan, Leela John, Emmanuelle Vaast, Adam S Ptolemy, Samer A Faraj, Eugene Kolker, Richard G H Cotton
No abstract text is available yet for this article.
December 1, 2011: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/22563365/pharmacogenomic-research-in-south-africa-lessons-learned-and-future-opportunities-in-the-rainbow-nation
#15
Louise Warnich, Britt I Drögemöller, Michael S Pepper, Collet Dandara, Galen E B Wright
South Africa, like many other developing countries, stands to benefit from novel diagnostics and drugs developed by pharmacogenomics guidance due to high prevalence of disease burden in the region. This includes both communicable (e.g., HIV/AIDS and tuberculosis) and non-communicable (e.g., diabetes and cardiovascular) diseases. For example, although only 0.7% of the world's population lives in South Africa, the country carries 17% of the global HIV/AIDS burden and 5% of the global tuberculosis burden. Nobel Peace Prize Laureate Archbishop Emeritus Desmond Tutu has coined the term Rainbow Nation, referring to a land of wealth in its many diverse peoples and cultures...
September 2011: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/22279516/forward-look-tenth-anniversary-of-the-human-genome-sequence-and-21-century-postgenomics-global-health-a-close-up-on-africa-and-women-s-health
#16
Sanaa M Kamal, Louise Warnich, Lynnette R Ferguson, Sanjeeva Srivastava, Sandipan Ray, Denise Avard, Yann Joly, Michael Le Huynh, Madeline Page, Mario Masellis, Edward S Dove, David Gurwitz, Vural Ozdemir
No abstract text is available yet for this article.
September 1, 2011: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/22162984/targeting-bcl-2-in-herceptin-resistant-breast-cancer-cell-lines
#17
JOURNAL ARTICLE
Anatasha Crawford, Rita Nahta
Acquired resistance to Herceptin is a major clinical problem in the treatment of HER2-overexpressing breast cancer. Understanding the molecular mechanisms leading to resistance will allow identification of novel therapeutic targets and predictors of therapeutic response. To this end, up-regulation of anti-apoptotic proteins has been associated with resistance to the HER2-targeted drug lapatinib, but has not yet been linked to Herceptin resistance. The aim of the current study was to determine if the Bcl-2 anti-apoptotic protein is a potential therapeutic target in cells with acquired Herceptin resistance...
September 2011: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/21892378/stem-cell-transplantation-for-hematological-malignancies-prospects-for-personalized-medicine-and-co-therapy-with-mesenchymal-stem-cells
#18
JOURNAL ARTICLE
Shyam A Patel, Pranela Rameshwar
Bone marrow transplantation is a form of cell therapy that has been in practice for decades for the treatment of hematological disorders and solid tumors. Immunosuppressive therapy has been a mainstay for treatment, but the severity of the adverse effects has made it an undesirable choice. Mesenchymal stem cells (MSCs), which reside in the vascular regions of the bone marrow, have been shown to serve as cellular support for the hematopoietic stem cell (HSC) niche. Furthermore, the immune suppressive properties of MSCs have been explored in the treatment of inflammatory and autoimmune disorders...
September 1, 2011: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/22282718/ethical-and-policy-considerations-in-the-application-of-pharmacogenomic-testing-for-tardive-dyskinesia-case-study-of-the-dopamine-d3-receptor
#19
Michel C F Shamy, Clement Zai, Vincenzo S Basile, James L Kennedy, Daniel J Müller, Mario Masellis
Tardive dyskinesia (TD) is a serious adverse effect often associated with the first generation antipsychotic medications used in the management of mental health disorders such as schizophrenia. Pharmacogenomics is the study of human genomic variation in relation to individual and population variability in medication response and side effects. Neuropsychiatry is one of the clinical domains in which pharmacogenomic approaches have been extensively studied. In the late 1990s, the Glycine9 (Gly9) allele of the Serine-9-Glycine (Ser9Gly) polymorphism in dopamine D3 receptor gene (DRD3) was found to be associated with both a liability to, and worsened severity of, TD in schizophrenic patients treated with typical antipsychotics...
June 1, 2011: Current Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/22279515/personalized-medicine-in-the-age-of-pharmacoproteomics-a-close-up-on-india-and-need-for-social-science-engagement-for-responsible-innovation-in-post-proteomic-biology
#20
Panga Jaipal Reddy, Rekha Jain, Young-Ki Paik, Robin Downey, Adam S Ptolemy, Vural Ozdemir, Sanjeeva Srivastava
No abstract text is available yet for this article.
March 1, 2011: Current Pharmacogenomics and Personalized Medicine
journal
journal
42121
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.